Involvement of puromycin-sensitive aminopeptidase in proteolysis of tau protein in cultured cells, and attenuated proteolysis of frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) mutant tau

Psychogeriatrics

Volumn 9, Issue 4, 2009, Pages 157-166

  Yanagi, Kentaro ^a   Tanaka, Toshihisa ^a   Kato, Kiyoko ^a   Sadik, Golam ^a   Morihara, Takashi ^a   Kudo, Takashi ^a   Takeda, Masatoshi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

FTDP 17.; Phosporylation; Proteolysis; Puromycin sensitive aminopeptidase; Tau protein

Indexed keywords

AMINOPEPTIDASE; ANTIBODY; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; FRONTOTEMPORAL DEMENTIA PARKINSONISM LINKED TO CHROMOSOME 17; LACTACYSTIN; METHIONINE; MUTANT PROTEIN; PROTEINASE; PUROMYCIN; SERINE; SMALL INTERFERING RNA; SULFUR 35; TAU PROTEIN; THREONINE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL FRACTIONATION; CELL STRAIN COS7; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

ALLELES; AMINOPEPTIDASES; ANIMALS; CELL DEATH; CELL LINE, TUMOR; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 17; COS CELLS; DNA MUTATIONAL ANALYSIS; FRONTOTEMPORAL DEMENTIA; HUMANS; TAU PROTEINS; TAUOPATHIES; TRANSFECTION;

EID: 77954434948     PISSN: 13463500     EISSN: 14798301     Source Type: Journal    
DOI: 10.1111/j.1479-8301.2010.00307.x     Document Type: Article

References (31)

1. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 1986, 261:6084-6089.
2. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 1986, 83:4913-4917.
3. Love S, Saitoh T, Quijada S, Cole GM, Terry RD. Alz-50, ubiquitin and tau immunoreactivity of neurofibrillary tangles, Pick bodies and Lewy bodies. J Neuropathol Exp Neurol 1988, 47:393-405.
4. Uchihara T, Mitani K, Mori H, Kondo H, Yamada M, Ikeda K. Abnormal cytoskeletal pathology peculiar to corticobasal degeneration is different from that of Alzheimer's disease or progressive supranuclear palsy. Acta Neuropathol 1994, 88:379-383.
5. Mori H, Nishimura M, Namba Y, Oda M. Corticobasal degeneration: A disease with widespread appearance of abnormal tau and neurofibrillary tangles, and its relation to progressive supranuclear palsy. Acta Neuropathol 1994, 88:113-121.
6. Hutton M, Lendon CL, Rizzu P. Association of missense and 5′-splice-site mutations in tau with inherited dementia FTDP-17. Nature 1998, 393:702-705.
7. Lindwall G, Cole RD. Phosphorylation affects the ability of tau protein to promote microtubule assembly. J Biol Chem 1984, 259:5301-5305.
8. Barton AJ, Harrison PJ, Najlerahim A. Increased tau messenger RNA in Alzheimer's disease hippocampus. Am J Pathol 1990, 137:497-502.
9. Yang LS, Ksiezak-Reding H. Calpain-induced proteolysis of normal human tau and tau associated with paired helical filaments. Eur J Biochem 1995, 233:9-17.
10. Yang LS, Gordon-Krajcer W, Ksiezak-Reding H. Tau released from paired helical filaments with formic acid or guanidine is susceptible to calpain-mediated proteolysis. J Neurochem 1997, 69:1548-1558.
11. Kenessey A, Nacharaju P, Ko LW, Yen SH. Degradation of tau by lysosomal enzyme cathepsin D: Implication for Alzheimer neurofibrillary degeneration. J Neyrochem 1997, 69:2026-2038.
12. Canu N, Dus L, Barbato C. Tau cleavage and dephosphorylation in cerebellar granule neurons undergoing apoptosis. J Neurosci 1998, 18:7061-7074.
13. Olesen OF. Proteolytic degradation of microtubule associated protein tau by thrombin. Biochem Biophys Res Commun 1994, 201:716-721.
14. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998, 67:425-479.
15. Goldberg AL. Protein degradation and protection against misfold or damaged proteins. Nature 2003, 426:895-899.
16. Feuillette S, Blard O, Lecourtois M. Tau is not normally degraded by the proteasome. J Neurosci Res 2005, 80:400-405.
17. Delobel P, Leroy O, Hamdane M. Proteasome inhibition and Tau proteolysis: An unexpected regulation. FEBS Lett 2005, 579:1-5.
18. Terman A, Gustafsson B, Brunk UT. Autophagy, organelles and ageing. J Pathol 2007, 211:134-143.
19. Hara T, Nakamura K, Matsui M. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 2006, 441:885-889.
20. Boland B, Kumar A, Lee S. Autophagy induction and autophagosome clearance in neurons: Relationship to autophagic pathology in Alzheimer's disease. J Neurosci 2008, 28:6926-6937.
21. Hamano T, Gendron TF, Causevic E. Autophagic-lysosomal perturbation enhances tau aggregation in transfectants with induced wild-type tau expression. Eur J Neurosci 2008, 27:1119-1130.
22. Karsten SL, Sang TK, Gehman LT. A genomic screen for modifiers of tauopathy identifies puromycin-sensitive aminopeptidase as an inhibitor of tau-induced neurodegeneration. Neuron 2006, 51:549-560.
23. Sengupta S, Horowitz PM, Karsten SL. Degradation of tau protein by puromycin-sensitive aminopeptidase in vitro. Biochemistry 2006, 45:15111-15119.
24. Rizzu P, Joosse M, Ravid R, Hoogeveen A, Kamphorst W, van Swieten JC, Willemsen R, Heutink P. Mutation-dependent aggregation of tau protein and its selective depletion from the soluble fraction in brain of P301L FTDP-17 patients. Hum Mol Genet 2000, 9:3075-3082.
25. Zhao J, Ren Y, Jiang Q, Feng J. Parkin is recruited to the centrosome in response to inhibition of proteasomes. J Cell Sci 2003, 116:4011-4019.
26. Nakaso K, Yoshimoto Y, Yano H, Takeshima T, Nakashima K. p53-mediated mitochondrial dysfunction by proteasome inhibition in dopaminergic SH-SY5Y cells. Neurosci Lett 2003, 354:213-216.
27. Szpaderska AM, Frankfater A. An intracellular form of cathepsin B contributes to invasiveness in cancer. Cancer Res 2001, 61:3493-3500.
28. Constam DB, Tobler AR, Rensing-Ehl A, Kemler I, Hersh LB, Fontana A. Puromycin-sensitive aminopeptidase. Sequence analysis, expression, and functional characterization. J Biol Chem 1995, 270:26931-26939.
29. Litersky JM, Johnson GV. Phosphorylation by cAMP-dependent protein kinase inhibits the degradation of tau by calpain. J Biol Chem 1992, 267:1563-1568.
30. Mack TG, Dayanandan R, Van Slegtenhorst M. Tau proteins with frontotemporal dementia-17 mutations have both altered expression levels and phosphorylation profiles in differentiated neuroblastoma cells. Neuroscience 2001, 108:701-712.
31. Alonso AC, Zaidi T, Grundke-Iqbal I, Iqbal K. Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci USA 1994, 91:5562-5566.